From October 28 to October 30, the annual Summit of the International Coalition of Drug Regulators (#ICMRA) takes place in Rome, in which a delegation of the Russian Healthcare Supervision takes part
These days, from October 28 to 30, the annual Summit of the International Coalition of Drug Regulators (#ICMRA) is taking place in Rome, in which a delegation of the Russian Healthcare Supervision Committee, headed by the head of the Russian Healthcare Supervision M.A. Murashko, takes part. A three-day meeting of regulators is held to exchange experiences and build trust between regulators to ensure better quality medicines. You can learn more about ICMRA at http://www.icmra.info/drupal/en/home.
Currently, ICMRA brings together the heads of 29 drug regulatory agencies from all regions of the world. The World Health Organization is an observer and works closely with ICMRA. Roszdravnadzor has been a member of ICMRA since 2016, thanks to which the further improvement of activities in the field of providing Russian citizens with high-quality, effective and safe medicines continues.
The theme of this year’s Summit is: “Developing Challenges in Science and Regulation” and related issues of the best and optimal consideration of innovations in regulatory matters.
The following topics are also considered and discussed at the Summit: regulation of circulation and traceability of the movement of medical products; the fight against the circulation of counterfeit and counterfeit medicines; creation of unified global databases for monitoring the circulation of medical products; multiregional clinical trials; patient-oriented clinical trials and specialized studies for special populations; pharmacovigilance; building competencies and enhancing regulatory capabilities; assistance in the accelerated development and launch of innovative drugs on the market and the development of processes for their accelerated registration; exchange of best regulatory practices to ensure public access to quality, effective, safe, innovative medicines. This time, special attention is paid to highly personalized new treatment methods, such as modern advanced therapy drugs (#ATMP), which “are unprecedented innovative treatment methods that affect health care planning and regulation systems.”